EPIZYME, INC. (NASDAQ:EPZM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders |
Epizyme, Inc. (the Company) held its Annual Meeting of
Stockholders on June22, 2017. The following is a summary of the
matters voted on at that meeting.
a) |
The stockholders of the Company elected Andrew R. Allen, M.D., Ph.D., Kenneth Bate and Robert B. Bazemore as class I directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2020. The results of the stockholders vote with respect to the election of the class I directors were as follows: |
|
|
Votes For |
Votes Withheld |
Broker Non-Votes |
|||||||||
|
|
27,389,634 | 19,801,669 | 8,470,131 | |||||||||
|
|
40,848,738 | 6,342,565 | 8,470,131 | |||||||||
|
|
46,915,485 | 275,818 | 8,470,131 |
b) |
The stockholders of the Company ratified the selection of Ernst Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. The results of the stockholders vote with respect to such ratification were as follows: |
|
|
|
|
|
|||
| 55,588,266 | 49,392 | 23,776 |
About EPIZYME, INC. (NASDAQ:EPZM)
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.
